Faqja kryesoreWXIBF • OTCMKTS
add
WuXi Biologics (Cayman) Inc
Mbyllja e fundit
2,50 USD
Diapazoni vjetor
1,30 USD - 6,60 USD
Kapitalizimi i tregut
70,05 mld HKD
Volumi mesatar
311,00
Raporti çmim/fitim
-
Të ardhurat e dividendit
-
Bursa kryesore
HKG
Lajmet nga tregu
MarketWatch
23 orë më parë
The stock market is ready for its melt-up as investors ignore growing risks
0,047%
Financa
Deklarimi mbi të ardhurat
Të ardhurat
Të ardhurat neto
| (CNY) | qer 2024info | Ndryshimi nga V/V |
|---|---|---|
Të ardhurat | 4,29 mld | 0,97% |
Kostoja operative | 765,14 mln | 21,62% |
Të ardhurat neto | 749,54 mln | -33,86% |
Marzhi i fitimit neto | 17,48 | -34,51% |
Fitimet për aksion | — | — |
EBITDA | 1,24 mld | -13,32% |
Norma efektive tatimore | 11,36% | — |
Bilanci
Aktivet në total
Pasivet në total
| (CNY) | qer 2024info | Ndryshimi nga V/V |
|---|---|---|
Investime afatshkurtra dhe në para fizike | 9,53 mld | 9,60% |
Aktivet në total | 56,11 mld | 7,60% |
Pasivet në total | 11,46 mld | -12,46% |
Kapitali aksioner në total | 44,64 mld | — |
Numri i aksioneve të aksionerëve | 4,15 mld | — |
Çmimi për të rezervuar | 0,26 | — |
Kthimi nga aktivet | 4,05% | — |
Kthimi nga kapitali | 4,62% | — |
Fluksi i parave
Ndryshimi neto i parave në dorë
| (CNY) | qer 2024info | Ndryshimi nga V/V |
|---|---|---|
Të ardhurat neto | 749,54 mln | -33,86% |
Paratë nga veprimtaritë | 651,06 mln | -52,65% |
Paratë nga investimi | -191,26 mln | 75,93% |
Paratë nga financimi | -737,79 mln | -684,70% |
Ndryshimi neto i parave në dorë | -258,16 mln | -153,79% |
Fluksi i lirë i parave | 350,65 mln | 52,56% |
Informacione
WuXi Biologics is a global Contract Research Development and Manufacturing Organization that provides open-access, integrated technology platforms for biologics drug development.
WuXi Biologics' roots date back to 2010, and began building out capabilities and facilities required for biologics discovery, development and GMP manufacturing. WuXi Biologics went public on the Hong Kong Stock Exchange in June 2017.
As of 2021, WuXi Biologics has 18 manufacturing sites including ten in China, three in the United States, two in Ireland, two in Germany, and one in Singapore.
In August 2020, WuXi Biologics was selected to become a component of the Hang Seng Index in Hong Kong.
In January 2024, WuXi Biologics' share price fell on news that the United States Congress had introduced legislation to block any federal government contracts with the company due to national security concerns. The concerns stem from allegations, denied by the company, that it has worked closely with the People's Liberation Army as a part of the Chinese Communist Party's military-civil fusion strategy. Wikipedia
Drejtori ekzekutiv
Themeluar
2010
Faqja në internet
Punonjësit
12 435
